Stock Screener App

Frei -

Installieren

3.77

1.89% 0.07

after-market

Handel nachbörslich: 3.77

Sab Biotherapeutics Inc (SABS)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Sab Biotherapeutics Inc Aktie (SABS) Neueste Nachrichten

Perceptive Advisors discloses 7.3% SAB Biotherapeutics (SABS) stake via Master Fund - Stock Titan

Caligan Partners (SABS) discloses 7.97M SAB Biotherapeutics shares in amended 13G - Stock Titan

Commodore Capital discloses 8.95M-share position in SAB Biotherapeutics (SABS) - Stock Titan

Vivo funds (SABS) report capped 9.99% stakes via preferred stock and warrants - Stock Titan

Woodline Partners (SABS) discloses 5.46M-share beneficial stake in SAB Biotherapeutics - Stock Titan

Balyasny Asset Management (SABS) discloses 7.2M-share SAB Biotherapeutics position capped at 9.99% - Stock Titan

Adage discloses 8.38% SAB Biotherapeutics (SABS) ownership in Schedule 13G - Stock Titan

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

SAB Biotherapeutics Inc (SABS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

RA Capital group discloses 9.9% SAB Biotherapeutics (SABS) stake capped by ownership blockers - Stock Titan

What is HC Wainwright's Estimate for SABS Q3 Earnings? - MarketBeat

Q3 EPS Estimate for SAB Biotherapeutics Boosted by Analyst - MarketBeat

SAB Biotherapeutics (NASDAQ:SABS) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat

H.C. Wainwright Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $10 - Moomoo

SAB Biotherapeutics Q2 Earnings Call Highlights - MarketBeat

SABS FY2030 EPS Boosted by Brookline Capital Markets - marketbeat.com

SAB Biotherapeutics (SABS) Rises 1.43% to $3.9 — Key Resistance at $4.09 in FocusVolume Spike Alerts - dars.gov.et

SAB Biotherapeutics (NASDAQ:SABS) Posts Earnings Results, Hits Estimates - MarketBeat

SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ... - Yahoo Finance

Earnings call transcript: SAB Bio posts wider Q2 2026 loss as trial momentum builds - Investing.com Nigeria

SAB Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

SAB Biotherapeutics, Inc. Q2 2026: Net loss $(22.5M), EPS $(0.28) — 10-Q Summary - TradingView

SAB Biotherapeutics (NASDAQ: SABS) posts Q2 loss after March 2026 stock offering - Stock Titan

SAB BIO Reports Q2 2026 Results, Expands SAB-142 Type 1 Diabetes Trials and Secures Breakthrough T1D Grant for PRISE-hATG Study - Quiver Quantitative

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - The Manila Times

Press Release: SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - Moomoo

SAB Biotherapeutics Reports $22.5M Net Loss in Q2 2026 Amid Balance Sheet Growth - Kalkine Media

SAB Biotherapeutics, Inc. Financial Disclosures & SEC Filings - TradingView

SAB Biotherapeutics Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView

SAB Biotherapeutics (NASDAQ:SABS) Downgraded by Wall Street Zen to Strong Sell - MarketBeat

SAB BIO schedules Aug. 6 webcast for second-quarter results - Stock Titan

SAB Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:SABS - TradingView

SABS|SAB Biotherapeutics Inc|Price:3.435|Chg%:-0.075 - TradingKey

SAB Biotherapeutics Inc (SABS) Institutional Confidence - TradingKey

SAB Biotherapeutics Inc (SABS) Valuation: PE, PB & Fair Value Analysis - TradingKey

SABS|SAB Biotherapeutics Inc|Price:3.900|Chg%:+0.050 - TradingKey

SABS Technical Analysis & ETF Price Forecast - Intellectia AI

SAB Biotherapeutics Inc (SABS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

SAB Biotherapeutics Inc (SABS) Balance Sheet - TradingKey

SABSW Plunges 43% to Penny Level: SAB Biotherapeutics Warrant Hits New LowHull Moving Average - dars.gov.et

SAB Biotherapeutics Inc (SABS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

SAB Biotherapeutics Inc (SABS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

SAB Biotherapeutics Inc (SABS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

TradingKey - TradingKey

SABS|SAB Biotherapeutics Inc|Price:3.510|Chg%:-0.070 - TradingKey

SAB Biotherapeutics (NASDAQ:SABS) Upgraded to "Sell" at Wall Street Zen - MarketBeat

SAB Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:SABSW - TradingView

ETFs Investing in SAB Biotherapeutics, Inc. Stocks - TradingView

Monashee Investment Management LLC Invests $1.92 Million in SAB Biotherapeutics, Inc. $SABS - marketbeat.com

SAB Biotherapeutics (SABS) Slides 3.4% as Stock Tests Key Support LevelsPositive Gamma - dars.gov.et

SAB Biotherapeutics (NASDAQ:SABS) Trading Up 0.6%Still a Buy? - MarketBeat

SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment - Yahoo Finance

SAB Biotherapeutics (SABS) Short Interest & Short Float | Updated Jul 2026 $SABS - MarketBeat

SAB Biotherapeutics (SABS) Edges Lower as Stock Tests Key Support LevelsCorrective Wave - DonanımHaber

SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial - TipRanks

Breakthrough T1D Awards Grant for SAB-142 PRISE-hATG Study to Advance Type 1 Diabetes Therapies Beyond 100 Days Post-Diagnosis – Minichart - Minichart

Breakthrough T1D funds PRISE-hATG to study SAB-142 in Stage 3 type 1 diabetes - TradingView

Grant backs SAB Biotherapeutics (NASDAQ: SABS) PRISE-hATG Stage 3 T1D trial - Stock Titan

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes - The Manila Times

Breakthrough T1D backs SAB-142 study beyond the first 100 days - Stock Titan

Wall Street Analysts Lift SAB Biotherapeutics Stock Over Diabetes Drug - HarianBasis.co

Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target? - Yahoo Finance

SAB Biotherapeutics, Inc. Warrant 2021-22.10.26 on SAB Biotherap Financial Disclosures & SEC Filings - TradingView

Price to sales forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView

SABSW Plunges to Penny Level as Biotech Warrant Faces Continued Selling PressureSupport Level Bounce - dars.gov.et

Barclays Initiates Overweight Rating on SAB Biotherapeutics, Signaling Positive Sector SentimentGross Profit Margin - dars.gov.et

Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS) - Yahoo Finance

MRNA

$64.46

1.80%

ROIV

$36.24

0.11%

RPRX

$59.45

1.45%

INSM

$128.32

3.70%

ALNY

$224.60

1.77%

ONC

$362.51

4.33%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters